Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans

Vaccine

Volumn 28, Issue 50, 2010, Pages 7881-7889

  Bett, Andrew J ^a   Dubey, Sheri A ^a   Mehrotra, Devan V ^a   Guan, Liming ^a   Long, Romnie ^a   Anderson, Kiersten ^a   Collins, Kelly ^a   Gaunt, Christine ^a   Fernandez, Rose ^a   Cole, Suzanne ^a   Meschino, Steve ^a   Tang, Aimin ^a   Sun, Xiao ^a   Gurunathan, Sanjay ^a   Tartaglia, Jim ^b   Robertson, Michael N ^a   Shiver, John W ^a   Casimiro, Danilo R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

HIV vaccine; Human; IFN ELISPOT; Rhesus monkey

Indexed keywords

AD5GAG ALVAC VACCINE; ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MRKAD5 GAG VACCINE; MRKAD5 HIV 1 CLADE B GAG POL NEF VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; V1JNS GAG AD5GAG VACCINE; V1JNS GAG VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DNA VECTOR; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; VACCINATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; GENES, GAG; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MACACA MULATTA; MODELS, ANIMAL; T-LYMPHOCYTES; VACCINES, DNA;

EID: 78650235664     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.079     Document Type: Article

References (47)

1. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002, 76:6138-6146.
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
3. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998.
4. Koup R.A., Safrit J.T., Cao Y.Z., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
5. + lymphocytes. Science 1999, 283:857-860.
6. Shiver J.W., Fu T.-M., Chen L., Casimiro D.R., Davies M., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
7. Caley I.J., Betts M.R., Irlbeck D.M., Davis N.L., Swanstrom R., Frelinger J.A., et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 1997, 71:3031-3038.
8. Casimiro D.R., Chen L., Fu T.-M., Evans R.K., Caulfield M.J., Davies M.-E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia and replication-defective adenoviral vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.
9. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999, 180:290-298.
10. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999, 73:7524-7532.
11. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006, 194:1638-1649.
12. Catanzaro A.T., Roederer M., Koup R.A., Bailer R.T., Enama M.E., Nason M.C., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25:4085-4092.
13. Goepfert P.A., Horton H., McElrath M.J., Gurunathan S., Ferrari G., Tomaras G.D., et al. High-dose recombinant canarypox vaccine expressing HIV-1 protein in seronegative human subjects. J Infect Dis 2005, 192:1249-1259.
14. Gupta K., Hudgens M., Corey L., McElrath M.J., Weinhold K., Montefiori D.C., et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002, 29:254-261.
15. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46:1769-1781.
16. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
17. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
18. Youil R., Toner T.J., Su Q., Casimiro D., Shiver J.W., Chen L., et al. Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses. Hum Gene Ther 2003, 14:1017-1034.
19. Chapman B.S., Thayer R.M., Vincent K.A., Haigwood N.L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 1991, 19:3979-3986.
20. Goodwin E.C., Rottman F.M. The 3'-flanking sequence of the bovine growth hormone gene contains novel elements required for efficient and accurate polyadenylation. J Biol Chem 1992, 267:16330-16334.
21. Human retroviruses and AIDS 1995: a compilation and analysis of nucleic acid and amino acid sequences 1995, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. G. Mayers, B. Korber, B.H. Hahn (Eds.).
22. Lathe R. Synthetic oligonucleotide probes deduced from amino acid sequence data: theoretical and practical considerations. J Mol Biol 1985, 183:1-12.
23. Davies J.F., Hostomska Z., Hostomsky Z., Jordan S.R., Matthews D.A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991, 252:88-95.
24. Larder B.A., Purifoy D.J., Powell K.L., Darby G. Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 1987, 327:716-717.
25. Larder B.A., Kemp S.D., Purifoy D.J. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A 1989, 86:4803-4807.
26. Leavitt A.D., Shiue L., Varmus H.E. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J Biol Chem 1993, 268:2113-2119.
27. Mizrahi V., Usdin M.T., Harington A., Dudding L.R. Site-directed mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase. Nucleic Acids Res. 1990, 18:5359-5363.
28. Schatz O., Cromme F.V., Gruninger-Leitch F., Le Grice S.F. Point mutations in conserved amino acid residues within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNAse H function. FEBS Lett. 1989, 257:311-314.
29. Wiskerchen M., Muesing M.A. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995, 69:376-386.
30. Liang X., Fu T.-M., Xie H., Emini E.A., Shiver J.W. Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. Vaccine 2002, 20:3413-3421.
31. Evans R.K., Zhu D.-M., Casimiro D.R., Nawrocki D.K., Mach H., Troutman R.D., et al. Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. J Pharm Sci 2004, 93:1924-1939.
32. Hartikka J., Geall A., Bozoukova V., Kurniadi D., Rusalov D., Enas J., et al. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 2008, 10:770-782.
33. Newman M.J., Actor J.K., Balusubramanian M., Jagannath C. Use of nonionic block copolymers in vaccines and therapeutics. Crit Rev Ther Drug Carrier Syst 1998, 15:89-142.
34. Todd C.W., Lee E., Balusubramanian M., Shah H., Henk W.G., Younger L.E., et al. Systematic development of a block copolymer adjuvant for trivalent influenza virus vaccine. Dev Biol Stand 1998, 92:341-351.
35. Casimiro D.R., Bett A.J., Fu T.-M., Davies M.E., Tang A., Wilson K.A., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004, 78:11434-11438.
36. Ferrari G., Berend C., Ottinger J., Dodge R., Bartlet J., Toso J., et al. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood 1997, 90:2406-2416.
37. Asmuth D.M., Brown E.L., DiNubile M.J., Sun X., del Rio C., Harro C., et al. Comparative cell-mediated immunogenicity of DNA/DNA DNA/adenovirus tyae 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime -boost regimens. J Infect Dis 2010, 201:132-141.
38. Harro C., Robertson M.N., Lally M., O'neill L., Edupuganti S., Goepfert P.A., et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV-1 clade B Gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009, 25:103-114.
39. Dubey S., Clair J., Fu T.-M., Guan L., Long L.R., Mogg R., et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV seronegative clinical trial participants using an optimized and validated ELISPOT assay. J Acquir Immune Defic Syndr 2007, 45:20-27.
40. Fu T.-M., Dubey S.A., Mehrotra D.V., Freed D.C., Trigona W.L., Adams-Muhler L., et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007, 23:67-76.
41. Yang Z., Wyatt L.S., Kong W., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003, 77:799-803.
42. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev 2008, 8:247-258.
43. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W.B., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
44. + T cells. Blood 2006, 107:4781-4789.
45. Cox K.S., Clair J.H., Prokop M.T., Sykes K.J., Dubey S.A., Shiver J.W., et al. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 2008, 82:8161-8171.
46. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194:1650-1660.
47. McCormack S., Stohr W., Barber T., Bart P.-A., Harari A., Moog C., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.